Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians' choices in hepatitis C therapy and social (macro-) allocation decision-making.The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients should be carefully informed, particularly on treatment deferral, and widespread information on these therapies should be implemented; (3) since treatment was proven to be cost-effective, its use is acceptable respecting resource macro-allocation. Concerning individual (micro-) location criteria: (a) criteria for eligibility to treatment should be clearly identified and updated periodically; (b) information on criteria for eligibility/deferral to treatment for specific patients' subgroups should be made widely known.Interferon-based regimens will disappear from use within the next year, with the introduction of highly effective/tolerable combination regimens of direct-acting antivirals, thus profoundly changing social choices. Nonetheless, our model could support future ethical assessment since the evaluation pertaining ethical domains remains generally applicable.

Sacchini, D., Craxì, L., Refolo, P., Minacori, R., Cicchetti, A., Gasbarrini, A., et al. (2015). Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. DIGESTIVE AND LIVER DISEASE, 47(5), 351-355 [10.1016/j.dld.2014.11.011].

Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors

Fagiuoli S
2015

Abstract

Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians' choices in hepatitis C therapy and social (macro-) allocation decision-making.The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients should be carefully informed, particularly on treatment deferral, and widespread information on these therapies should be implemented; (3) since treatment was proven to be cost-effective, its use is acceptable respecting resource macro-allocation. Concerning individual (micro-) location criteria: (a) criteria for eligibility to treatment should be clearly identified and updated periodically; (b) information on criteria for eligibility/deferral to treatment for specific patients' subgroups should be made widely known.Interferon-based regimens will disappear from use within the next year, with the introduction of highly effective/tolerable combination regimens of direct-acting antivirals, thus profoundly changing social choices. Nonetheless, our model could support future ethical assessment since the evaluation pertaining ethical domains remains generally applicable.
Articolo in rivista - Articolo scientifico
Direct-acting antivirals; Ethics; Health technology assessment; Hepatitis C virus;
English
351
355
5
Sacchini, D., Craxì, L., Refolo, P., Minacori, R., Cicchetti, A., Gasbarrini, A., et al. (2015). Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. DIGESTIVE AND LIVER DISEASE, 47(5), 351-355 [10.1016/j.dld.2014.11.011].
Sacchini, D; Craxì, L; Refolo, P; Minacori, R; Cicchetti, A; Gasbarrini, A; Cammà, C; Spagnolo, A; WEF Study, G; Fagiuoli, S
File in questo prodotto:
File Dimensione Formato  
sacchini DLD 2015.pdf

Solo gestori archivio

Dimensione 309.32 kB
Formato Adobe PDF
309.32 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353974
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
Social impact